BIG
FDMT icon

Brooklyn Investment Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Brooklyn Investment Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,318
Closed -$102K – 1907
2025
Q4 		$102K Sell
13,318
-12,846
-49% -$130K ﹤0.01% 1463
2025
Q3 		$100K Sell
26,164
-30,699
-54% -$183K 0.01% 642
2025
Q2 		$211K Buy
56,863
+52,646
+1,248% +$185K 0.03% 586
2025
Q1 		$13.6K Buy
+4,217
New +$19.9K ﹤0.01% 1364

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Brooklyn Investment Group's FDMT Position: Q1 2026 in Review

Brooklyn Investment Group sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 13,318 shares — an estimated $102K sold.

Brooklyn Investment Group first reported a position in FDMT in Q1 2025 and held it in 4 quarters. The position peaked at $211K in Q2 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Brooklyn Investment Group reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 13,318 4D Molecular Therapeutics shares in Q1 2026, an estimated $102K.
  • Brooklyn Investment Group first reported a position in 4D Molecular Therapeutics in Q1 2025 and held it in 4 quarters.
  • Brooklyn Investment Group's 4D Molecular Therapeutics position peaked at $211K in Q2 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.